Bioscience Animal Health Valuation
Is BIS-R undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of BIS-R when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: BIS-R (THB3.78) is trading above our estimate of fair value (THB0.47)
Significantly Below Fair Value: BIS-R is trading above our estimate of fair value.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for BIS-R?
Other financial metrics that can be useful for relative valuation.
What is BIS-R's n/a Ratio? | |
---|---|
n/a | 0x |
n/a | n/a |
Market Cap | ฿1.19b |
Key Statistics | |
---|---|
Enterprise Value/Revenue | 0.5x |
Enterprise Value/EBITDA | 11.7x |
PEG Ratio | n/a |
Price to Earnings Ratio vs Peers
How does BIS-R's PE Ratio compare to its peers?
Company | Forward PE | Estimated Growth | Market Cap |
---|---|---|---|
Peer Average | 24.6x | ||
SEI SEI Medical | 32.3x | 34.7% | ฿867.0m |
WINMED Winnergy Medical | 31.5x | n/a | ฿800.0m |
SMD SaintMed | 23.1x | n/a | ฿864.0m |
BIZ Business Alignment | 11.6x | n/a | ฿2.1b |
BIS-R Bioscience Animal Health | 19.2x | n/a | ฿1.2b |
Price-To-Earnings vs Peers: BIS-R is good value based on its Price-To-Earnings Ratio (19.2x) compared to the peer average (24.6x).
Price to Earnings Ratio vs Industry
How does BIS-R's PE Ratio compare vs other companies in the TH Healthcare Industry?
Price-To-Earnings vs Industry: BIS-R is good value based on its Price-To-Earnings Ratio (19.2x) compared to the TH Healthcare industry average (24x).
Price to Earnings Ratio vs Fair Ratio
What is BIS-R's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
Fair Ratio | |
---|---|
Current PE Ratio | 19.2x |
Fair PE Ratio | n/a |
Price-To-Earnings vs Fair Ratio: Insufficient data to calculate BIS-R's Price-To-Earnings Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.